Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
Rhea-AI Summary
Tevogen (NASDAQ:TVGN) has announced promising financial projections for its pipeline product TVGN 116, targeting liver cancer prevention in high-risk chronic Hepatitis B patients. The company estimates a substantial 5-year cumulative top-line revenue of approximately $6.5 billion.
The risk-adjusted Net Present Value (rNPV) for TVGN 116 is projected to exceed $325 million in the US market alone. These projections are based on current market analysis and unmet medical needs. The company's development approach emphasizes a unique, accelerated, and cost-efficient drug development model, which they believe could serve as a template for sustainable medical innovation.
The success of their first clinical-stage product, TVGN 489, demonstrates the company's ability to rapidly achieve development milestones, with risk adjustments being reset at each milestone in the product development lifecycle.
Positive
- Projected 5-year top-line revenue of ~$6.5 billion for TVGN 116
- Estimated risk-adjusted Net Present Value (rNPV) exceeding $325 million in US market
- Cost-efficient and faster drug development model
- Demonstrated progress with first clinical-stage product TVGN 489
Negative
- Additional capital raising may be needed to execute business plan
- Significant regulatory and development risks ahead
- Limited operating history as stated in risk factors
- Potential challenges in maintaining effective internal controls
News Market Reaction
On the day this news was published, TVGNW declined 0.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~
$325 million in the US alone.
WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections.
The TVGN 116 cumulative 5-year top-line revenue forecast is estimated to be ~
The current rNPV projection for this internally developed asset exceeds ~
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the projected 5-year revenue for Tevogen's TVGN 116 liver cancer prevention drug?
What is the estimated risk-adjusted Net Present Value (rNPV) for TVGN 116 in the US market?
How does Tevogen's drug development model differ from traditional approaches?
What are the main risks associated with Tevogen's TVGN 116 development?
What is TVGN 116 designed to treat?
